To study this, we evaluated the changes in the population of CD8+ T cells specific to tyrosinase-related protein 2 (TRP2), a well-known B16F10 melanoma antigen, in the blood and primary tumor-draining lymph nodes in the cured mice. This evidence concerns the gene DCT and melanoma.